Patents by Inventor Kang-Yell Choi

Kang-Yell Choi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200223824
    Abstract: A composition for promoting longitudinal bone growth, according to the present invention, promotes the proliferation of the chondrocytes and the differentiation of the osteoblasts and has effects of simultaneously increasing longitudinal bone length and thickness (bone density), and thus has an advantage of being widely prescribable to various age groups, thereby being usable as a pharmaceutical composition for promoting the growth of longitudinal bone length and thickness. An indirubin derivative according to the present invention has prevention or treatment effects through oral administration and has an excellent competitive price unlike conventional hormone-based therapeutic agents.
    Type: Application
    Filed: April 10, 2018
    Publication date: July 16, 2020
    Inventors: Kang-Yell Choi, Gyoonhee Han, Jeong-Ha Hwang, Sehee Choi, Changmok Oh
  • Publication number: 20200179425
    Abstract: The present invention is about composition for preventing hair loss or promoting hair growth comprising indirubin derivatives; and one or more selected from the group consisting of Euodia daniellii extract, Persicaria hydropiper extract, Hovenia dulcis extract, methyl vanillate, hesperidin and quercitrin; as an active ingredient. In addition, one or more selected from the group consisting of Euodia daniellii extract, Persicaria hydropiper extract, Hovenia dulcis extract, methyl vanillate, hesperidin and quercitrin of the present invention is a natural-derived composition with little toxicity to cells. Indirubin derivatives are stable compounds that have been found to have little toxicity to the human body, and therefore, when used in a mixture thereof, there are advantages in that they do not exhibit adverse effects on the human body, unlike conventional steroid drugs.
    Type: Application
    Filed: July 31, 2018
    Publication date: June 11, 2020
    Applicant: CK BIOTECH
    Inventors: Kang-Yell CHOI, Jiyong SHIM, Yeong Chan RYU, Jiyeon PARK
  • Publication number: 20200046706
    Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.
    Type: Application
    Filed: August 20, 2019
    Publication date: February 13, 2020
    Inventors: Kang-Yell CHOI, Mi-Yeon KIM, Sungho HAN
  • Patent number: 10485802
    Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: November 26, 2019
    Assignee: GENUV Inc.
    Inventors: Kang-Yell Choi, Mi-Yeon Kim, Sungho Han
  • Patent number: 10179132
    Abstract: Disclosed is a composition for inducing the differentiation of neural stem cells into dopaminergic neurons. The composition includes the compound represented by Formula 1 (“AS703026”) as a MEK 1/2 inhibitor. Also disclosed is a method for inducing the differentiation of neural stem cells into dopaminergic neurons by using the composition. Dopaminergic neurons whose differentiation from neural stem cells is induced by the composition and method can be applied to cell replacement therapies and gene therapies for the treatment of neurodegenerative diseases, such as Parkinson's disease, or can be widely used as materials for the examination of drug effects or numerous studies in the development of new drugs.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: January 15, 2019
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Kang-Yell Choi, Mi-Yeon Kim, Yeong-Mun Kim
  • Publication number: 20180360901
    Abstract: The invention relates to a composition containing extracts of the fruit of Hovenia dulcis Thunb., gallocatechin, and methyl vanillate as active ingredients for preventing and treating bone disease. The extracts of the fruit of Hovenia dulcis Thunb., the gallocatechin, and the methyl vanillate according to the present invention are natural materials and thus cause no side effects, and may activate the Wnt/?-catenin pathway to promote bone formation rather than inhibiting bone decomposition, and therefore may be effective in treating osteoporosis and related diseases. In addition, the extracts of the fruit of Hovenia dulcis Thunb., the gallocatechin, and the methyl vanillate according to the present invention may have the effects regrowing hair and preventing and treating wounds and metabolic diseases related to the activation of Wnt/?-catenin pathway.
    Type: Application
    Filed: August 24, 2018
    Publication date: December 20, 2018
    Inventors: Kang Yell Choi, Pu Hyeon Cha
  • Patent number: 10149833
    Abstract: The present invention provides a composition comprising an indirubin derivative for stimulating longitudinal bone growth. Because the composition for stimulating longitudinal bone growth according to the present invention is shown to be effective in longitudinal bone growth, it may be used not only as a composition for stimulating longitudinal bone growth, but also as a pharmaceutical composition for treating or preventing short stature, microplasia, dwarfism, or precocious puberty.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: December 11, 2018
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Kang-Yell Choi, Hyun-Yi Kim, Sehee Choi
  • Publication number: 20180169102
    Abstract: The present invention relates to a method of inducing neuro-regeneration comprising administering a MEK 1/2 inhibitor to a patient in need thereof. In the present invention, the MEK1/2 inhibitor induces neuro-regeneration by differentiating neural stem cells into neurons, by protecting neural stem cells and neurons against cytotoxicity of amyloid-betas, or by both of the above. Also, the present invention relates to a method of protecting neurons against neuronal loss or damage comprising administering a MEK1/2 inhibitor. In addition, this invention relates to a method of preventing or treating neurodegenerative disease due to neuronal loss or damage for patients in need thereof comprising administering a MEK 1/2 inhibitor.
    Type: Application
    Filed: February 14, 2018
    Publication date: June 21, 2018
    Inventors: Kang-Yell CHOI, Mi-Yeon Kim, Sungho Han
  • Publication number: 20180117007
    Abstract: The present invention provides a composition comprising an indirubin derivative for stimulating longitudinal bone growth. Because the composition for stimulating longitudinal bone growth according to the present invention is shown to be effective in longitudinal bone growth, it may be used not only as a composition for stimulating longitudinal bone growth, but also as a pharmaceutical composition for treating or preventing short stature, microplasia, dwarfism, or precocious puberty.
    Type: Application
    Filed: December 26, 2017
    Publication date: May 3, 2018
    Inventors: Kang-Yell Choi, Hyun Yi Kim, Sehee Choi
  • Patent number: 9763994
    Abstract: The present disclosure relates to a composition for promoting wound healing that may be used as a pharmaceutical composition, or a cosmetic composition for promoting wound healing, which contains a polypeptide including an amino acid sequence of SEQ ID NO 1. The composition may be usefully used for a wound care drug or a functional cosmetic product for wound care.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: September 19, 2017
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Kang-Yell Choi, Soung-Hoon Lee, Hyun-Yi Kim
  • Publication number: 20170209451
    Abstract: Disclosed is a composition for inducing the differentiation of neural stem cells into dopaminergic neurons. The composition includes the compound represented by Formula 1 (“AS703026”) as a MEK 1/2 inhibitor. Also disclosed is a method for inducing the differentiation of neural stem cells into dopaminergic neurons by using the composition. Dopaminergic neurons whose differentiation from neural stem cells is induced by the composition and method can be applied to cell replacement therapies and gene therapies for the treatment of neurodegenerative diseases, such as Parkinson's disease, or can be widely used as materials for the examination of drug effects or numerous studies in the development of new drugs.
    Type: Application
    Filed: March 10, 2017
    Publication date: July 27, 2017
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Kang-Yell CHOI, Mi-Yeon KIM, Yeong-Mun KIM
  • Publication number: 20160346329
    Abstract: Disclosed is a composition for inducing the differentiation of neural stem cells into dopaminergic neurons. The composition includes the compound represented by Formula 1 (“AS703026”) as a MEK 1/2 inhibitor. Also disclosed is a method for inducing the differentiation of neural stem cells into dopaminergic neurons by using the composition. Dopaminergic neurons whose differentiation from neural stem cells is induced by the composition and method can be applied to cell replacement therapies and gene therapies for the treatment of neurodegenerative diseases, such as Parkinson's disease, or can be widely used as materials for the examination of drug effects or numerous studies in the development of new drugs.
    Type: Application
    Filed: October 7, 2015
    Publication date: December 1, 2016
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Kang-Yell CHOI, Mi-Yeon Kim, Yeong-Mun Kim
  • Publication number: 20160271104
    Abstract: The present invention provides a composition comprising an indirubin derivative for stimulating longitudinal bone growth. Because the composition for stimulating longitudinal bone growth according to the present invention is shown to be effective in longitudinal bone growth, it may be used not only as a composition for stimulating longitudinal bone growth, but also as a pharmaceutical composition for treating or preventing short stature, microplasia, dwarfism, or precocious puberty.
    Type: Application
    Filed: July 10, 2014
    Publication date: September 22, 2016
    Inventors: Kang-Yell Choi, Hyun Yi Kim, Sehee Choi
  • Publication number: 20160038555
    Abstract: The invention relates to a composition containing extracts of the fruit of Hoveniadulcis Thunb., gallocatechin, and methyl vanillate as active ingredients for preventing and treating bone disease. The extracts of the fruit of Hoveniadulcis Thunb., the gallocatechin, and the methyl vanillate according to the present invention are natural materials and thus cause no side effects, and may activate the Wnt/?-catenin pathway to promote bone formation rather than inhibiting bone decomposition, and therefore may be effective in treating osteoporosis and related diseases. In addition, the extracts of the fruit of Hoveniadulcis Thunb., the gallocatechin, and the methyl vanillate according to the present invention may have the effects regrowing hair and preventing and treating wounds and metabolic diseases related to the activation of Wnt/?-catenin pathway.
    Type: Application
    Filed: March 30, 2012
    Publication date: February 11, 2016
    Inventors: Kang Yell Choi, Pu Hyeon Cha
  • Publication number: 20150309029
    Abstract: Methods of diagnosing cancer and screening for an anti-cancer drug using Ras are provided. Ras has a very significant role as a prevalent proto-oncogene which has abnormalities in most forms of cancer, and thus the methods of diagnosing cancer and screening for an anti-cancer drug using Ras may be applied to various forms of cancer. The generation of various forms of cancer in the early stages may be determined by examining whether or not phosphorylation of Ras occurs at Thr-144 and Thr-148 sites. By such a mechanism, an anti-cancer drug having excellent anti-cancer effectiveness may be screened, or the effectiveness of the anti-cancer drug may be tested.
    Type: Application
    Filed: February 17, 2015
    Publication date: October 29, 2015
    Inventors: Kang-Yell CHOI, Woo-Jeong JEONG
  • Patent number: 9150630
    Abstract: There are provided Idbf (inhibitor of Dvl and bone formation) which is a novel Dvl-binding protein that binds to Dvl to inhibit signal transduction carried out through the Wnt/?-catenin signaling pathway, a gene for coding for the same, the use thereof, and the use of an inhibitor of the Idbf. The Idbf was known to be expressed by activation of the Wnt/?-catenin signaling pathway and bind to Dvl to block signal transduction carried out through the Wnt/?-catenin signaling pathway. Therefore, the Idbf can be used in development of medicines for inhibiting the signal transduction carried out through the Wnt/?-catenin signaling pathway, and an Idbf inhibitor can be used in preparation of medicines for activating the signal transduction carried out through the Wnt/?-catenin signaling pathway.
    Type: Grant
    Filed: August 3, 2009
    Date of Patent: October 6, 2015
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Kang-Yell Choi, Hyun-Yi Kim, Ju-Yong Yoon
  • Publication number: 20150224167
    Abstract: The present disclosure relates to a composition for promoting wound healing that may be used as a pharmaceutical composition, or a cosmetic composition for promoting wound healing, which contains a polypeptide including an amino acid sequence of SEQ ID NO 1. The composition may be usefully used for a wound care drug or a functional cosmetic product for wound care.
    Type: Application
    Filed: December 11, 2014
    Publication date: August 13, 2015
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: KANG-YELL CHOI, SOUNG-HOON LEE, HYUN-YI KIM
  • Patent number: 8952060
    Abstract: Provided is a composition for preventing hair loss or promoting hair growth including valproic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The composition may be applied to various industrial fields, including pharmaceutical, cosmetic and beauty aid industries.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: February 10, 2015
    Assignee: Amorepacific Corporation
    Inventors: Hyoung-Jun Kim, Won Seok Park, Hyun Ju Koh, Pil Joon Park, Su Na Kim, Kang-Yell Choi, Ju-Yong Yoon, Soung-Hoon Lee
  • Publication number: 20120065262
    Abstract: Provided is a composition for preventing hair loss or promoting hair growth including valproic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The composition may be applied to various industrial fields, including pharmaceutical, cosmetic and beauty aid industries.
    Type: Application
    Filed: May 11, 2010
    Publication date: March 15, 2012
    Inventors: Hyoung-Jun Kim, Won Seok Park, Hyun Ju Koh, Pil Joon Park, Su Na Kim, Kang-Yell Choi, Ju-Yong Yoon, Soung-Hoon Lee
  • Publication number: 20110189693
    Abstract: Methods of diagnosing cancer and screening for an anti-cancer drug using Ras are provided. Ras has a very significant role as a prevalent proto-oncogene which has abnormalities in most forms of cancer, and thus the methods of diagnosing cancer and screening for an anti-cancer drug using Ras may be applied to various forms of cancer. The generation of various forms of cancer in the early stages may be determined by examining whether or not phosphorylation of Ras occurs at Thr-144 and Thr-148 sites, By such a mechanism, an anti-cancer drug having excellent anti-cancer effectiveness may be screened, or the effectiveness of the anti-cancer drug may be tested.
    Type: Application
    Filed: February 1, 2011
    Publication date: August 4, 2011
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Kang-Yell CHOI, Woo-Jeong JEONG